Xhance (Fluticasone Propionate Nasal Spray, for Intranasal Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Trelegy Ellipta (Fluticasone Furoate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Trelegy Ellipta for COPD FDA Approves Trelegy Ellipta for COPD
The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA approves GSK ’ s 3-in-1 Trelega Ellipta inhaler
The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today. The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 -- Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food& Drug Administration (FDA) approved the Company ’s New Drug Application (NDA) for Xhance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 19, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 18, 2017 Category: Drugs & Pharmacology Source Type: news

CHMP Backs Two New Inhalers Inhalers for COPD CHMP Backs Two New Inhalers Inhalers for COPD
Elebrato Ellipta and Trelegy Ellipta contain the triple combination of fluticasone furoate, umeclidinium, and vilanterol and are for inadequately controlled moderate to severe COPD in adults.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

EMA Panel Backs Two New Inhalers for COPD EMA Panel Backs Two New Inhalers for COPD
Elebrato Ellipta and Trelegy Ellipta contain the triple combination of fluticasone furoate, umeclidinium, and vilanterol and are for inadequately controlled moderate to severe COPD in adults.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

GSK ’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister site, Drug Deli...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Fluticasone Furoate Slows Loss of Lung Function in COPD
Alone or in combination, reduces rate of FEV1 decline in those with moderate COPD and high risk of CVD (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Pharmacy, Pulmonology, Journal, Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

GSK files supplementary NDA for asthma treatment arnuity ellipta
GSK has submitted a supplementary new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use of arnuity ellipta (fluticasone furoate) as a maintenance treatment of children with asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2017 Category: Drugs & Pharmacology Source Type: news

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease. Get the full story at our sister site, Drug Delivery Business News. The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news